Premium support is a general term used to describe an approach to reform Medicare that aims to reduce the growth in Medicare spending. These FAQs raise and discuss basic questions about the possible effects of a premium support system for Medicare beneficiaries, the federal budget, health care providers, and private health plans.
- view as grid
- view as list
With its inclusion in the House GOP health plan released last month, the idea of converting Medicare into a premium support system once again features prominently in Capitol Hill policy discussions about the future of Medicare, the federal health insurance program that covers 57 million seniors and people with disabilities.…
In this Wall Street Journal Think Tank column, Drew Altman looks at the debate about increases in Obamacare premiums and public misperceptions about who is and is not affected by them.
Donor government funding to support HIV efforts in low- and middle-income countries fell for the first time in five years in 2015, decreasing from US$8.6 billion in 2014 to US$7.5 billion, finds a new report from the Kaiser Family Foundation and the Joint United Nations Programme on HIV/AIDS (UNAIDS) released in…
Financing the Response to HIV in Low- and Middle-Income Countries: International Assistance from Donor Governments in 2015
This report, Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance from Donor Governments in 2015, tracks funding levels of the donor governments that collectively provide the bulk of international assistance for AIDS through bilateral programs and contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria. Donor government funding to support HIV efforts in low- and middle-income countries fell for the first time in five years in 2015, decreasing from US$8.6 billion in 2014 to US$7.5 billion.
Using Medicaid State Drug Utilization Data, this brief presents the 50 most costly drugs before rebates used by the Medicaid program over the January 2014 through June 2015 period. It then examines reasons why these drugs are so costly; explores case studies on opioids, hepatitis C drugs, and the drug Abilify; and considers policy implications.